(vianews) - shares of transgene (cac 40: tng.pa) rose by a staggering 17.44% in 5 sessions from €1.72 to €2.02 at 14:05 est on wednesday, after two consecutive sessions in a row of gains. cac 40 is falling 0.02% to €7,207.46, following the last session's upward trend.
about transgene
transgene sa, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer in france. it involved in developing tg4050, a therapeutic vaccine that is in phase i clinical trial for the treatment of ovarian cancer, and head and neck cancers; tg4001, a therapeutic vaccine, which is in phase ii clinical trial for the treatment of hpv-positive cancers; tg6002, an oncolytic virus that is in phase i/iia clinical trial for the treatment of gastrointestinal and colorectal cancers; and bt-001, an oncolytic virus, which is in phase i/ii clinical trial for the treatment of solid tumors. the company also develops tg1050, a therapeutic vaccine for the treatment of hepatitis b; tg6050 for the treatment of non-small cell lung cancer, and pexa-vec, an oncolytic virus for the treatment of solid tumors. it has strategic collaboration agreements with astrazeneca, merck kgaa, pfizer, and nec corporation; licensing agreements with sillajen, ascend biopharmaceutical, and valneva; and agreements with merck & co, sanofi, bioinvent, and randox. transgene sa was incorporated in 1979 and is headquartered in illkirch-graffenstaden, france. transgene sa is a subsidiary of tsgh sas.
earnings per share
as for profitability, transgene has a trailing twelve months eps of €-0.33.
more news about transgene (tng.pa).